Home›Rankings›Cagrilintide

MetabolicPreliminary grade

Cagrilintide

Novo Nordisk's long-acting amylin analogue for weight management, potent when combined, modest as monotherapy.

Verdict, C · Emerging / Mixed

Amylin analogue with a clean mechanistic rationale and reasonable safety in trials, but the real story is in combination. Standalone approval is unlikely; wait for CagriSema data and a licensed supply path.

PepScore / 100

CEmerging / Mixed

How we compute this →

Overview

Cagrilintide is a long-acting amylin analogue designed for weekly subcutaneous dosing, studied both as monotherapy and in combination with semaglutide (CagriSema). Phase-2 monotherapy data showed approximately 10-11% weight loss, while the combination shows markedly greater effect. It has not received regulatory approval as a standalone compound, and no verified consumer supply exists.

PepScore Breakdown, the four axes

Evidence

35% weight

61/100

How strong is the published human science?

Human data depth22/40

Regulatory & registry status20/30

Reproducibility & consistency12/20

Mechanism characterized in humans7/10

Sourcing & COA

30% weightOur moat

35/100

Can a buyer obtain an independently-verified, high-purity version?, our proprietary layer.

Independent + portal-verifiable testing12/35

Method transparency (HPLC + MS + endotoxin/sterility, methods stated)9/25

Lot-matched + recent9/25

Independent corroboration5/15

Safety & Risk

25% weight

58/100

What is the real-world harm potential?

Documented AEs / toxicity22/40

Contraindication breadth14/25

Regulatory warnings12/20

Therapeutic index / margin10/15

Practicality

10% weight

48/100

How easy is it to actually run a verified version?

Verified-source availability12/35

Cost / value per cycle11/25

Reconstitution & administration16/25

Storage & stability9/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI, see methodology.

Want a clinical path?

Talk to a licensed provider about Cagrilintide and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice, for educational purposes.

PepScore51/100 · C

Last gradedJune 28, 2026

Next re-grade triggerRegulatory approval of CagriSema combination would be the most likely path to verified supply.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only, no spam.

Educational only, not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links, this never affects grades. Consult a licensed healthcare provider before using any compound.